^18F-FDG PET/CT评估转移性肾癌靶向治疗疗效及预后的应用  

Application of^18F-FDG PET/CT in evaluating the efficacy and prognosis of targeted therapy for metastatic renal cell carcinoma

作　　者：周春燕[1] 段东[1] Zhou Chunyan;Duan Dong(Department of Nuclear Medicine,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院核医学科,400016

出　　处：《国际放射医学核医学杂志》2020年第6期386-393,共8页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：转移性肾癌(mRCC)对放疗和化疗均不敏感,患者预后差。随着分子靶向治疗的发展,舒尼替尼和索拉非尼等多种靶向药物极大地改善了mRCC的预后,但靶向治疗对部分患者的疗效不佳,靶向药物还可能引起相关的不良反应。因此,早期无创性评估肿瘤对靶向药物的反应,从而为患者选择最佳治疗方案尤为重要。然而国内外的研究者至今尚未找到理想的生物标志物。作为一种功能影像,PET/CT在许多肿瘤中的临床价值已被认可,近年来其在mRCC中的应用也逐渐增多。笔者就PET/CT在评估mRCC靶向治疗疗效及预后中的价值及局限性作一综述。Metastatic renal cell carcinoma(mRCC)is insensitive to both radiotherapy and chemotherapy;hence,the prognosis of patients with mRCC is poor.With the development of molecular targeted therapy,various targeted drugs,such as sunitinib and sorafenib,have greatly improved the prognosis of mRCC.However,targeted therapy is not effective for some patients,and targeted drugs may also cause related adverse reactions.Therefore,early non-invasive assessment of tumor response to targeted drugs is particularly important to allow patients and physicians to decide on the best course of treatment.However,researchers worldwide have not yet found an ideal biomarker for mRCC.As a functional imaging technology,the clinical value of PET/CT has been recognized in diagnosing numerous tumors.In recent years,the application of PET/CT in mRCC has gradually increased.This review focuses on the application of PET/CT in patients with mRCC.In particular,this review discusses the value and limitations of the application of PET/CT in evaluating targeted treatment response and prognosis.

关 键 词：转移性肾癌 氟脱氧葡萄糖F18 正电子发射断层显像术 体层摄影术 X线计算机 疗效 预后 

分 类 号：R737.11[医药卫生—肿瘤] R730.44[医药卫生—临床医学]